Save time and get answers to complex questions with AI chat
Can i take anti histamine with statin?Does lipitor's effectiveness decrease with high fat meals?Antiox mebendazole price?When does guselkumab patent expire?Excipients list used in dexamethasone creams?
See the DrugPatentWatch profile for eliquis
It’s a big win for the Bristol Myers Squibb (BMS)–Pfizer alliance—and for the broader generic‑drug industry, too. Here’s a quick rundown of what’s happened and why it matters.
Bottom line: The Federal Circuit’s decision is a win for BMS–Pfizer because it solidifies Eliquis’ market dominance, gives the alliance a stronger position in cross‑licensing negotiations, and keeps drug prices higher for the foreseeable future. For patients and the generic market, the decision postpones cheaper alternatives, while for the industry it underscores the importance of a strong, defensible patent portfolio in today’s litigation‑heavy environment.
Other Questions About Eliquis :